Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat

Drug Profile

Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat

Alternative Names: Elvitegravir/Truvada/GS 9350; EVG/FTC/TDF/cobicistat FDC Quad tablet; Quad; Stribild

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 26 Oct 2016 Efficacy data from the phase IIIb trial in HIV-1 infections released by Gilead Sciences
  • 15 Dec 2014 Launched prior to this date for HIV-1 infections (Treatment-naive) in Luxembourg, Ireland, Denmark, Finland, Austria, Belgium, Greece, Poland, Portugal, Sweden, Slovakia, Switzerland, Norway and Iceland (PO)
  • 01 Dec 2014 Gilead Sciences completes a phase III clinical trial in HIV-1 infections (Treatment-experienced) in Australia, Austria, Belgium, Canada, Germany, Italy, Portugal, Puerto Rico, Spain, the United Kingdom and the USA (NCT01495702; EudraCT2011-004963-56)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top